MX2020006198A - Compuesto mejorado para tratamiento de insuficiencia cardiaca. - Google Patents

Compuesto mejorado para tratamiento de insuficiencia cardiaca.

Info

Publication number
MX2020006198A
MX2020006198A MX2020006198A MX2020006198A MX2020006198A MX 2020006198 A MX2020006198 A MX 2020006198A MX 2020006198 A MX2020006198 A MX 2020006198A MX 2020006198 A MX2020006198 A MX 2020006198A MX 2020006198 A MX2020006198 A MX 2020006198A
Authority
MX
Mexico
Prior art keywords
treatment
heart failure
improved compound
compound
improved
Prior art date
Application number
MX2020006198A
Other languages
English (en)
Inventor
Thomas Thum
Sandor Batkai
Ariana Foinquinos
Original Assignee
Medizinische Hochschule Hannover
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Hochschule Hannover filed Critical Medizinische Hochschule Hannover
Publication of MX2020006198A publication Critical patent/MX2020006198A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un oligonucleótido que es un inhibidor efectivo del microRNA miR-132 y a su uso en medicina, particularmente en la prevención o tratamiento de trastornos cardiacos y/o fibróticos.
MX2020006198A 2017-12-15 2018-12-14 Compuesto mejorado para tratamiento de insuficiencia cardiaca. MX2020006198A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762599050P 2017-12-15 2017-12-15
EP17207738 2017-12-15
PCT/EP2018/085008 WO2019115788A1 (en) 2017-12-15 2018-12-14 Improved compound for treatment of heart failure

Publications (1)

Publication Number Publication Date
MX2020006198A true MX2020006198A (es) 2020-11-24

Family

ID=65023844

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006198A MX2020006198A (es) 2017-12-15 2018-12-14 Compuesto mejorado para tratamiento de insuficiencia cardiaca.

Country Status (20)

Country Link
US (2) US11208651B2 (es)
EP (1) EP3724336B1 (es)
JP (1) JP7253834B2 (es)
KR (1) KR20200104294A (es)
CN (1) CN111630168B (es)
AU (1) AU2018383013A1 (es)
BR (1) BR112020009532A2 (es)
CA (1) CA3084111A1 (es)
CL (1) CL2020001578A1 (es)
DK (1) DK3724336T3 (es)
ES (1) ES2910303T3 (es)
HU (1) HUE058867T2 (es)
IL (1) IL275273B1 (es)
MX (1) MX2020006198A (es)
PH (1) PH12020550589A1 (es)
PL (1) PL3724336T3 (es)
RS (1) RS63078B1 (es)
SI (1) SI3724336T1 (es)
WO (1) WO2019115788A1 (es)
ZA (1) ZA202002529B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114450067B (zh) * 2019-06-14 2024-03-15 卡迪奥尔药物有限公司 人受试者的心力衰竭的治疗

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
EP1791954A1 (en) * 2004-09-07 2007-06-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
US20070065840A1 (en) 2005-03-23 2007-03-22 Irena Naguibneva Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
CA2609142C (en) * 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic gene vectors comprising mirna target sequences
EP2364367B8 (en) * 2008-11-10 2017-08-23 Battelle Memorial Institute Method utilizing microrna for detecting interstitial lung disease
WO2010105096A2 (en) 2009-03-11 2010-09-16 University Of Massachusetts Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
US20120107825A1 (en) * 2010-11-01 2012-05-03 Winger Edward E Methods and compositions for assessing patients with reproductive failure using immune cell-derived microrna
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
ES2651515T3 (es) 2011-09-06 2018-01-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. La familia miARN-212/132 como diana terapéutica
CN103361428B (zh) * 2013-06-21 2016-06-22 徐州医学院 miRNA-132化合物在制备慢性疼痛诊断标志物及治疗药物中的应用
US10174320B2 (en) * 2014-09-21 2019-01-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Downregulating miR-132 for the treatment of lipid related disorders
CN114450067B (zh) * 2019-06-14 2024-03-15 卡迪奥尔药物有限公司 人受试者的心力衰竭的治疗
WO2022018269A1 (en) * 2020-07-23 2022-01-27 Johann Wolfgang Goethe-Universität Frankfurt Combinatorial inhibition of mirnas for treatment of heart failure
CN112043721B (zh) * 2020-09-04 2022-01-28 南通大学 miR-132-5p在制备神经再生药物或材料中的应用
CN115068632A (zh) * 2022-06-22 2022-09-20 华中科技大学同济医学院附属同济医院 Ago2在制备治疗心衰的药物方面的用途及其蛋白、基因、转化体、药物与制备方法

Also Published As

Publication number Publication date
ES2910303T3 (es) 2022-05-12
CL2020001578A1 (es) 2020-11-06
IL275273B1 (en) 2024-05-01
PL3724336T3 (pl) 2022-08-08
EP3724336A1 (en) 2020-10-21
RS63078B1 (sr) 2022-04-29
ZA202002529B (en) 2021-08-25
SI3724336T1 (sl) 2022-05-31
IL275273A (en) 2020-07-30
US20210180054A1 (en) 2021-06-17
AU2018383013A1 (en) 2020-06-11
US20220162597A1 (en) 2022-05-26
US11208651B2 (en) 2021-12-28
DK3724336T3 (da) 2022-03-21
WO2019115788A1 (en) 2019-06-20
KR20200104294A (ko) 2020-09-03
RU2020122587A (ru) 2022-01-10
CN111630168B (zh) 2023-09-22
PH12020550589A1 (en) 2021-04-26
JP2021506268A (ja) 2021-02-22
JP7253834B2 (ja) 2023-04-07
CA3084111A1 (en) 2019-06-20
EP3724336B1 (en) 2022-02-09
BR112020009532A2 (pt) 2020-11-03
HUE058867T2 (hu) 2022-09-28
RU2020122587A3 (es) 2022-01-10
CN111630168A (zh) 2020-09-04

Similar Documents

Publication Publication Date Title
PH12017500629A1 (en) Immuniregulatory agents
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
NZ732394A (en) Parg inhibitory compounds
PH12017501279A1 (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX2017014547A (es) Secuencias de uricasa mejoradas y metodos de tratamiento.
MX2017016347A (es) Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal.
WO2016004413A3 (en) Gls1 inhibitors for treating disease
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
MX2021007260A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
WO2016042561A3 (en) Downregulating mir-132 for the treatment of lipid related disorders
GEP20186939B (en) Medical treatments based on anamorelin
EA201692202A1 (ru) Способы лечения сердечно-сосудистых заболеваний
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
PH12020550589A1 (en) Improved compound for treatment of heart failure
MX2021015552A (es) Tratamiento de la insuficiencia cardiaca en individuos humanos.
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
EP3669880A4 (en) USE OF miR-18b IN THE PREVENTION, TREATMENT, OR DIAGNOSIS OF MUSCLE AND NEUROMUSCULAR DISEASE
MX2019012153A (es) N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso.
EA201790430A1 (ru) С-20 стероидные соединения, композиции и их применение для лечения травматического повреждения головного мозга (tbi), включая сотрясения мозга
WO2015162172A3 (en) Incrnas for therapy and diagnosis of angiogenesis